Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus MR Conversion in Stable Kidney Transplant Patients
NCT00282568Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2002
- Primary completion
- Oct 2008
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus + Wuzhi capsule in kidney transplant rejection, sponsored by Astellas Pharma. Primary endpoints: Area Under the Concentration-time Curve From Time 0 to 24 Hours, Maximum Observed Concentration at Day 21 and 4 more. Started Aug 2002; status: completed.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00282568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00282568.